Xanthine oxidase inhibitory lanostanoids from Ganoderma tsugae

Fitoterapia. 2013 Sep:89:231-8. doi: 10.1016/j.fitote.2013.06.006. Epub 2013 Jun 13.

Abstract

Two new lanostanoids, 3α-acetoxy-22-oxo-5α-lanosta-8,24-dien-21-oic acid, named tsugaric acid D (1) and 16α-hydroxy-3-oxo-5α-lanosta-6,8,24(24(1))-trien-21-oic acid, named tsugaric acid E (2) were isolated from the fruit bodies of Ganoderma tsugae. The structures 1 and 2 were determined by spectroscopic methods. Compound 1 and known compounds 3 and 6 exhibited significant inhibitory effects on xanthine oxidase (XO) activity with an IC50 values of 90.2±24.2, 116.1±3.0, and 181.9±5.8 μM, respectively. Known compound 5 was able to protect human keratinocytes against damage induced by UVB light, which showed 5 could protect keratinocytes from photodamage. The 1 and 5 μM 1 combined with 5 μM cisplatin, respectively, enhanced the cytotoxicity induced by cisplatin. It suggested that 1 and 5 μM 1 combined with low dose of cisplatin may enhance the therapeutic efficacy of cisplatin and reduce side effect and cisplatin resistant.

Keywords: Antioxidant; Cytotoxicity; Ganoderma tsugae; Lanostanoids; Photodamage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / chemistry
  • Antineoplastic Agents, Phytogenic / isolation & purification
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Antioxidants / chemistry
  • Antioxidants / isolation & purification
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use*
  • Biological Products / chemistry
  • Biological Products / pharmacology
  • Biological Products / therapeutic use*
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Fruiting Bodies, Fungal / chemistry
  • Ganoderma / chemistry*
  • Herb-Drug Interactions
  • Humans
  • Inhibitory Concentration 50
  • Keratinocytes / drug effects*
  • Keratinocytes / radiation effects
  • Lanosterol / analogs & derivatives*
  • Lanosterol / chemistry
  • Lanosterol / isolation & purification
  • Lanosterol / pharmacology
  • Lanosterol / therapeutic use
  • Male
  • Molecular Structure
  • Phytotherapy
  • Prostatic Neoplasms / drug therapy*
  • Radiation Injuries, Experimental / drug therapy
  • Skin Diseases / prevention & control
  • Xanthine Oxidase / antagonists & inhibitors*

Substances

  • Antineoplastic Agents, Phytogenic
  • Antioxidants
  • Biological Products
  • tsugaric acid
  • Lanosterol
  • Xanthine Oxidase
  • Cisplatin